Kevin Rakin has served on our board of directors since June 2020. Mr. Rakin was HighCape Capital Acquisition Corp’s Chief Executive Officer from June 2020 to June 2021. Since October 2013, Mr. Rakin has been a co-founder and partner of HighCape, a growth equity firm, and he brings more than 30 years of experience as an executive and investor in the life sciences industry. Previously, from June 2011 to November 2012, he served as the President of Shire Regenerative Medicine. From 2005, Mr. Rakin was the Chairman and Chief Executive Officer of Advanced BioHealing, Inc., a provider of regenerative medicine solutions until its sale to Shire, PLC in 2011. Before that, he served as an Executive-In-Residence at Canaan Partners, a venture capital firm until its merger with Clinical Data, Inc. in 2005. Mr. Rakin was also the co-founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a biotechnology company.
Mr. Rakin also currently serves on the board of directors of Brainstorm Cancer Therapeutics, Inc., CapeHaven Holding Company, LLC, CapeHaven, Inc., Elutia, Inc. (formerly Aziyo Biologics, Inc.) (Chairman), and Nyxoah S.A. Mr. Rakin previously served on the board of directors of Histogenics Corp., Oramed Pharmaceuticals, Inc. and Tela Bio Inc. Mr. Rakin holds an M.B.A. in business management from Columbia University and B.Com. (Hons) in finance and accounting from the University of Cape Town, South Africa. Mr. Rakin’s qualifications to serve on our board of directors include his extensive experience in the life sciences industry, as both an executive and an investor and his network of contacts in the industry.
